Ocata Therapeutics Inc  

(Public, NASDAQ:OCAT)   Watch this stock  
Find more results for OTC:ACTC
+0.08 (1.22%)
Mar 5 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.40 - 6.68
52 week 4.95 - 12.73
Open 6.51
Vol / Avg. 192,719.00/142,600.00
Mkt cap 226.99M
P/E     -
Div/yield     -
EPS -1.44
Shares 34.39M
Beta 1.07
Inst. own 0%
Mar 3, 2015
Ocata Therapeutics Inc at Cowen Health Care Conference
Feb 9, 2015
Ocata Therapeutics Inc at Biotechnology Industry Organization CEO & Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -9415.91% -13788.28%
Operating margin -9522.68% -13394.54%
EBITD margin - -10394.14%
Return on average assets -201.58% -500.18%
Return on average equity - -
Employees 38 -
CDP Score - -


33 Locke Dr
MARLBOROUGH, MA 01752-1167
United States - Map
+1-508-7561212 (Phone)
+1-508-2292333 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Ocata Therapeutics, Inc., formerly Advanced Cell Technology, Inc., is a biotechnology company focused on developing and commercializing human embryonic and adult stem cell technology in the emerging field of regenerative medicine. The Company has acquired, developed and maintained a portfolio of patents and patent applications that forms the base for its research and development efforts in the area of embryonic and adult stem cell research. The Company�s emerging field of treatment called regenerative medicine or cell therapy refers to treatments that are founded on the concept of producing new cells to replace malfunctioning or damaged cells as a vehicle to treat disease and injury. It focuses on the development of effective methods to generate replacement cells from both human embryonic and adult stem cells.

Officers and directors

Michael T. Heffernan Chairman of the Board
Age: 49
Bio & Compensation  - Reuters
Paul K. Wotton Ph.D. President, Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
Edward H. Myles CPA Chief Financial Officer, Executive Vice President - Corporate Development
Age: 42
Bio & Compensation  - Reuters
Eddy Anglade M.D. Executive Vice President - Clinical Development
Age: 52
Bio & Compensation  - Reuters
LeRoux Jooste Senior Vice President - Business Development, Chief Commercial Officer
Bio & Compensation  - Reuters
Robert P. Lanza M.D. Chief Scientific Officer
Age: 58
Bio & Compensation  - Reuters
John Heffernan Vice President - Manufacturing
Bio & Compensation  - Reuters
Robert S. Langer Independent Director
Age: 65
Bio & Compensation  - Reuters
Zohar Loshitzer Independent Director
Age: 56
Bio & Compensation  - Reuters
Gregory D. Perry Independent Director
Age: 54
Bio & Compensation  - Reuters